Analysed ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
10-04-2026
yahoo.com
Assessing Ascendis Pharma (ASND) Valuation After New COACH Trial Data And YUVIWEL Orphan Drug Exclusivity
10-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
09-04-2026
yahoo.com
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
08-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
07-04-2026
yahoo.com
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
06-04-2026
yahoo.com
How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma’s (ASND) Pipeline Strategy
06-04-2026
yahoo.com
What is the current price of ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ)?
The current price of ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) is $239.28.
ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) absolute price change since previous trading day?
The absolute price change of ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) since the previous trading day is $-2.43.
ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) percentage price change since previous trading day?
The percentage price change of ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) since the previous trading day is -1.0053%.
What is the most recent average sentiment score for ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ)?
The most recent average sentiment score for ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) is 63 out of 100.
What is the most recent average sentiment for ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ)?
The most recent sentiment for ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ) is .
SEC-8K** Filing Available For ASCENDIS PHARMA A/S - ADR (ASND:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.